Triptorelin

Generic Name: Triptorelin

Brand Names: Decapeptyl, Trelstar, Triptodur

Drug Type: Small Molecule

Chemical Formula: C_₆₄H_₈₂N_₁₈O_₁₃

CAS Number: 57773-63-4

Unique Ingredient Identifier: 9081Y98W2V

Background: Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men.

Indication: Triptorelin is indicated for the palliative treatment of advanced prostate cancer.

Associated Conditions: Advanced Prostate Cancer

Associated Therapies: Controlled ovarian hyperstimulation therapy

Clinical Trials

Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer

Phase 2

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Triptorelin 22.5 mg
Radiation: Brachytherapy

First Posted Date: 2011-06-15

Last Posted Date: 2019-09-18

Lead Sponsor: Ipsen

Target Recruit Count: 32

Registration Number: NCT01374087

Locations: 🇪🇸
H. Sanchinarro, Madrid, Spain
🇪🇸
H. Ramón y Cajal, Madrid, Spain
🇪🇸
H. de la Santa Creu i Sant Pau, Barcelona, Spain

and more 8 locations

Equivalence of Intramuscular (IM) Versus Subcutaneous (SC) Applications of Long Acting Pamorelin 11.25 mg

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Triptorelin Pamoate (Pamorelin® LA 11.25 mg)

First Posted Date: 2010-12-09

Last Posted Date: 2019-02-08

Lead Sponsor: Ipsen

Target Recruit Count: 109

Registration Number: NCT01257425

Locations: 🇩🇪
Urologische Klinik, Neunkirchen, Germany
🇩🇪
Praxis für Urologie, Wuppertal, Germany
🇩🇪
Kreiskrankenhaus, Abteilung Urologie, Bad Bergzabern, Germany

and more 1 locations

Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration

Phase 4

Completed

Conditions: Prostate Cancer

Interventions: Drug: Leuprolide acetate
Drug: Triptorelin pamoate

First Posted Date: 2010-07-13

Last Posted Date: 2013-09-06

Lead Sponsor: Watson Pharmaceuticals

Target Recruit Count: 118

Registration Number: NCT01161563

Locations: 🇺🇸
Watson Investigational Site, Norfolk, Virginia, United States

Efficiency of Gonadotropin-releasing Hormone (GnRH) Agonist in Preventing Chemotherapy Induced Ovarian Failure

Phase 2

Completed

Conditions: Alkylating Agents
Lymphoma
Fertility Preservation

Interventions: Drug: Norethisterone acetate
Drug: Triptorelin

First Posted Date: 2010-07-12

Last Posted Date: 2015-10-30

Lead Sponsor: Erasme University Hospital

Target Recruit Count: 118

Registration Number: NCT01160315

Locations: 🇫🇷
Hôpital Hotel Dieu, Paris, France
🇧🇪
AZ St Jan, Brugges, Belgium
🇧🇪
CHRU Lille, Lille, Belgium

and more 12 locations

Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: Triptorelin (Decapeptyl®)

First Posted Date: 2009-11-25

Last Posted Date: 2019-01-30

Lead Sponsor: Ipsen

Target Recruit Count: 339

Registration Number: NCT01020448

Locations: 🇪🇸
Hospital Juan Canalejo, Coruña, Spain
🇬🇧
Lister Hospital, Stevenage, United Kingdom
🇫🇷
Hôpital Pellegrin, Bordeaux, France

and more 56 locations

Single Dose Gonadotropin-releasing Hormone (GnRH) Agonist Administration in the Luteal Phase of GnRH Antagonist Stimulated ICSI-ET Cycles

Phase 3

Terminated

Conditions: Infertility

Interventions: Drug: triptorelin acetate
Drug: NaCl %0.9

First Posted Date: 2009-11-04

Last Posted Date: 2009-11-04

Lead Sponsor: V.K.V. American Hospital, Istanbul

Registration Number: NCT01007851

Locations: 🇹🇷
American Hospital, Istanbul, Turkey

Effects of Triptorelin Pamoate in Children With Precocious Puberty - Follow up Study

Phase 3

Completed

Conditions: Precocious Puberty

Interventions: Drug: Triptorelin (I.N.N.)

First Posted Date: 2009-05-29

Last Posted Date: 2019-01-15

Lead Sponsor: Ipsen

Target Recruit Count: 35

Registration Number: NCT00909844

Locations: 🇫🇷
Hôpital des Enfants, Toulouse, France
🇫🇷
Hôpital Hôtel Dieu (CHU), Angers, France
🇫🇷
Hôpital Flaubert, Le Havre, France

and more 7 locations

A 4 Year Combination Therapy of Growth Hormone and (GnRH) Agonist in Children With a Short Predicted Height

Phase 4

Active, not recruiting

Conditions: Idiopathic Short Stature

Interventions: Drug: somatropin
Drug: triptorelin

First Posted Date: 2009-02-11

Last Posted Date: 2023-07-28

Lead Sponsor: Belgian Study Group for Pediatric Endocrinology

Target Recruit Count: 44

Registration Number: NCT00840944

Locations: 🇧🇪
CHU ND-des Bruyères, Liege, Belgium
🇧🇪
Antwerp University Hospital, Edegem, Antwerpen, Belgium
🇧🇪
Kinderziekenhuis UZ Brussel, Brussel, Belgium

and more 3 locations